glp 1 for heart disease GLP-1 and the cardiovascular system Cardiovascular Protective Properties of GLP-1

In a cohort of 7 patients with DT2 and obesity, daily use of liraglutide 1.2mg achieved, after 10 weeks, a weight reduction of 5% and a decrease in BMI of 2kg/m2.80 In another study, 3 patients with DT2 and obesity achieved a decrease in BMI of between 0.8 and 3.8kg/m2 after 18 weeks with this same dose of liraglutide.81 Another 2 patients with obesity and DT2 achieved weight losses of more than 5kg and a decrease in BMI of 1.5 and 2kg/m2 after 6 weeks of treatment.82 Finally, in a series of 20 subjects with obesity and DT2, an average weight loss of 4.7kg was reported after 8 weeks of treatment with liraglutide 1.8mg.83 In most of these patients, improvements in the psoriasis area severity index (PASI) was observed, and on occasions, a decrease in psoriatic plaques

If your BMI is 40+ and you need substantial weight reduction for health reasons, the 20-25% body weight loss achievable with tirzepatide vastly exceeds the 10% typical of Qsymia

The drugs can also reduce the effectiveness of some forms of birth control, making unplanned pregnancies more likely

Anhedonia is not currently a formally established or quantified side effect of GLP-1 treatment